ABTSIKSIMAB (Abciximab).

     Synonym : ReoPro, ReoPro.

     Antiagregant new generation (established in early 1990). . "chimeric" is a monoclonal antibody. Received biotechnological method by combining FAB- factions mouse antibodies with human immunoglobulin. It has a specific ability to communicate with irreversible receptor IIb / IIIa platelets (changes the conformation linking arginin- glitsin- asparaginatnogo receptor site), thereby preventing lock (for those receptors) fibrinogena factor Villebranda and other adhesive molecules, and by providing powerful antiagregatnoe (antitromboticheskoe ) effect.

     Unlike synthetic competitive inhibitors IIb / IIIa receptor platelets (tirofibana, lamifibana and eptifibatida) abtsiksimab is high and long affinity to the above receptors, as well as a very short period of half-blood. Therefore, in introducing the current blood had an immediate effect, but the effect is necessary to maintain continuous cefuroxim.

     Applied (in combination with acetylsalicylic acid and intravenous heparin Infusion) for the prevention of thrombosis after angioplasticheskih operations (in the coronary arteries, etc.) for acute myocardial infarct, postinfarktnoy and unstable angina.

     Enter intravenous bolyusno in coronary angioplasty for 10-60 minutes until the operation is 0.25 mg / kg for 1 minute, then infuzionno at speeds of 0,125 µ g / kg per minute (up to 10 µ g of 1 min) for 12 h. In unstable angina drug introduction starting 24 hours before the operation cutaneous revaskulyarizatsii attack.

     Possible side effects : hemorrhage, arterial hypotension, aetiology, thrombocytopenia, rarely, allergic reactions.

     The drug is not suitable for domestic krovotecheniyah, haemorrhagic diathesis, anevrizme, severe arterial hypertension, thrombocytopenia, severe kidney or liver damage, pregnancy and breastfeeding.

     Before and after 12 and 24 h after the start of treatment should be determined Hematocrit and hemoglobin and within 2-4 and 24 hours of platelets in the blood.

      The operation reinforced by the anti, fabrinolitikov and other antiagregantov. Nevertheless, with appropriate monitoring while abtsiksimabom apply atsetilsalitsilovuyu acid (aspirin) and heparin in small doses.

     Using abtsiksimab only in hospital for severe condition.

     Product : 0.2% injection in vials of 5 and 20 ml.

Materials allowed to copy only with the active hyperlink to the handbook of medicines